Ribonucleic Acid News and Research

RSS
Magnetic nanoparticles for SARS-CoV-2 and other virus detection systems

Magnetic nanoparticles for SARS-CoV-2 and other virus detection systems

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

Study demonstrates differential alternative splicing in betacoronaviruses

Study demonstrates differential alternative splicing in betacoronaviruses

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

SARS-CoV-2 infection found in wild white-tailed deer in Canada

SARS-CoV-2 infection found in wild white-tailed deer in Canada

SARS-CoV-2 infection and vaccination-induced T cells cross-recognize Omicron

SARS-CoV-2 infection and vaccination-induced T cells cross-recognize Omicron

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

Attenuated tissue immune responses against SARS-CoV-2 in obese and non-obese patients

Attenuated tissue immune responses against SARS-CoV-2 in obese and non-obese patients

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Novel SARS-CoV-2 mutations reported in chronic HIV patients

Novel SARS-CoV-2 mutations reported in chronic HIV patients

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Paxlovid provides a glimpse into the future against SARS-CoV-2

Paxlovid provides a glimpse into the future against SARS-CoV-2

Is COVID-19 mRNA vaccination in children associated with subsequent multisystemic hyper-inflammatory syndrome?

Is COVID-19 mRNA vaccination in children associated with subsequent multisystemic hyper-inflammatory syndrome?

Antibodies to SARS-CoV-2 and infection risk in healthcare workers following mRNA vaccination

Antibodies to SARS-CoV-2 and infection risk in healthcare workers following mRNA vaccination

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.